360biolabs

Executive Summary

360biolabs, a BioAgilytix company headquartered in Melbourne, Australia, is a leading provider of comprehensive bioanalytical services for early-phase clinical trials. Specializing in pharmacokinetic, pharmacodynamic, immunogenicity, biomarker, and vaccine assays, the company leverages advanced platforms including LC-MS/MS, ELISA, and flow cytometry to support biotech and pharma clients across infectious diseases, immunology, oncology, and vaccines. Since its founding in 2015, 360biolabs has grown significantly, now employing over 1,000 staff and operating as a key platform within the BioAgilytix network. The company's strategic location in the Asia-Pacific region positions it to capture growing demand from global drug developers seeking high-quality, cost-effective bioanalytical solutions for early-stage development. With a strong track record and integration into a larger CRO ecosystem, 360biolabs is well-positioned to benefit from the expanding pipeline of novel therapeutics and vaccines.

Upcoming Catalysts (preview)

• Q3 2026Major new contract win for vaccine assay services80% success
• Q2 2026Expansion of LC-MS/MS biomarker testing capabilities90% success
• Q4 2026Announcement of strategic partnership with a top-20 pharma company60% success